Sofinnova Partners overview
Stories about Sofinnova Partners
Sofinnova Partners raises $540m
The Paris-based asset manager has held a final close for its growth capital fund.
Sofinnova Partners raises €333m
The Paris-based venture capital firm closed its ninth healthcare fund.
Sofinnova Partners raises €48m
The European venture capital firm closes specialised life sciences fund.
Sofinnova Partners raises €125m
The European venture capital firm closes largest European industrial biotech fund.
Sofinnova raises €106m for industrial biotech fund
The Paris-based life sciences specialist has held a first close on €106m for the fund, which is dedicated to renewable chemistry.
Sofinnova closes Fund XIII on €300m
The lifescience investor topped its €250 million target tapping investors primarily in Europe and some in North America.
Illinois Teachers’ commits $97m to Oaktree, Sofinnova
The $34.6bn pension has been ‘overhauling’ its private equity programme to expand its capabilities around co-investing, secondaries and international investments.
Sofinnova Partners contact information
Offices
7-11 Boulevard Haussmann, Paris, 75009, FranceContacts
| Name | Job title | Location | |
|---|---|---|---|
Key Contact Mr. Ahmed Fourati | Job titleInvestor Relations and Reporting Officer | LocationParis, France | Email  ---------- |
| Key ContactMs. Aziliz Le Roux | Job titleInvestor Relations Manager | LocationParis, France | Email ------ |
| Key ContactMs. Nathalie Loreaux | Job titleInvestor Relations and Reporting Manager | LocationParis, France | Email ------ |
| Mr. Christophe Blanche | Job titleChief Financial Officer | LocationParis, France | Email -------- |
Sofinnova Partners funds managed
Funds in market: 1
| Fund | Fund size | Open date | Strategy |
|---|---|---|---|
Fund size ----- | Open date- | Strategy ----------- | |
Closed funds: 22
| Fund | Fund size | Close date | Strategy |
|---|---|---|---|
Fund size --------- | Close dateSep 2026 | Strategy ------- | |
Fund size ------- | Close dateDec 2025 | Strategy ------- | |
Fund size ------- | Close dateMay 2025 | Strategy ---------- | |
Stories that mention Sofinnova Partners
Side Letter: PE's $160trn grail
Private equity's biggest hitters take aim at the $160 trillion retail market, according to panellists at IPEM Paris. Plus: PE and VC deal values hit a four-year low; and Australian private investments are outperforming publicly traded instruments. Here's today's brief, for our valued subscribers only.
GPs in crisis: Narrow your focus
Market downturns often widen the divide between winners and losers. Fund managers that find a specialisation are likely to gain an edge.
GP consolidation to deepen in difficult fundraising environment – IPEM panel
The high cost of operations, capital constraints and an attraction to specialists are all factors driving M&A activity among PE firms.
Bpifrance turns innovation into growth
The sovereign investor, which ranked 13th in this year’s list, is well known for encouraging its GPs to innovate sustainably and expand into new areas of investment.
The Nordic 'thought leader' LP that's sceptical of GPs going public
Swedish insurer Skandia Asset Management doesn't just go with the flow. Its head of private equity and infrastructure, Daniel Winther, discusses his bearish outlook on of continuation funds, sponsors listing and ESG targets.
CHART: The biggest dedicated life sciences capital raisers
Dedicated life sciences firms with strong AUM growth have been prime targets for larger GPs recently – here's a list of firms ranked by capital raised.
Side Letter: Advent's timely $26bn; Cathay's €500m health kick; UK's climate crackdown
Advent International's gargantuan fundraise should be well placed to capitalise on new take-private opportunities. Plus: Cathay Capital has joined the life sciences party and the UK is getting demanding when it comes to climate disclosures. Here's today's brief, for our valued subscribers only.
Side Letter: Horizon's Ukraine learnings; Apollo's €1bn life sciences buy; Onex fundraising warning
Horizon Capital's Lenna Koszarny discusses the Ukrainian firm's efforts to safeguard staff and portco employees in the wake of Russia's invasion. Plus: Apollo has become the latest firm to snap up a life sciences unit and Onex warns fundraising could take longer than usual. Here's today's brief, for our valued subscribers only.